Hoşal, Ali Şefik

Profile Picture
Name Variants
Hoşal, Ali Şefik
Hoşal A.
Hosal, S.
Ali Şefik, Hoşal
A., Hosal
H.,Ali Şefik
A.,Hoşal
Ali Sefik, Hosal
Hosal A.
A.Ş.Hoşal
Hosal, Sefik
A. Ş. Hoşal
H., Ali Şefik
Hoşal,A.Ş.
Hosal S.
H.,Ali Sefik
A.S.Hosal
Hoşal Ş.
Hosal,A.S.
H., Ali Sefik
Hosal, Ali Sefik
A. S. Hosal
Job Title
Profesor Doktor
Email Address
sefik.hosal@atilim.edu.tr
Main Affiliation
Surgical Sciences
Status
Website
ORCID ID
Scopus Author ID
6602627461
Turkish CoHE Profile ID
Google Scholar ID
WoS Researcher ID
Scholarly Output

3

Articles

2

Citation Count

22

Supervised Theses

0

Filters

2022 - 20243
Reset filters

Settings

Scholarly Output Search Results

Now showing 1 - 3 of 3
  • Thumbnail Image
    Article
    Citation - WoS: 6
    Citation - Scopus: 8
    Human Laryngeal Squamous Cell Carcinoma Cell Line Release of Endogenous Anandamide and 2-Arachidonoylglycerol, and Their Antiproliferative Effect Via Exogenous Supplementation: an in Vitro Study
    (Springer, 2022) Onay, Ovsen; Kose, Sevil; Suslu, Nilda; Korkusuz, Petek; Nemutlu, Emirhan; Aydin, Canset; Hosal, Sefik; Surgical Sciences; Nutrition and Dietetics
    The level of the major endocannabinoids anandamide (AEA) and 2-arachidonoylglycerol (2-AG) are altered in several types of carcinomas, and are known to regulate tumor growth. Thusly, this study hypothesized that the HEp-2 human laryngeal squamous cell carcinoma (LSCC) cell line releases AEA and 2-AG, and aimed to determine if their exogenous supplementation has an anti-proliferative effect in vitro. In this in vitro observational study a commercial human LSCC cell line (HEp-2) was used to test for endogenous AEA and 2-AG release via liquid chromatography-tandem mass spectrometry (LC-MS/MS). The anti-proliferative effect of AEA and 2-AG supplementation was evaluated via WST-1 proliferation assay. It was observed that the HEp-2 LSCC cell line released AEA and 2-AG; the median quantity of AEA released was 15.69 ng mL(-1) (range: 14.55-15.95 ng mL(-1)) and the median quantity of 2-AG released was 2.72 ng (-1) (range: 2.67-2.74 ng mL(-1)). Additionally, both AEA and 2-AG exhibited an anti-proliferative effect. The anti-proliferative effect of 2-AG was stronger than that of AEA. These findings suggest that AEA might function via a CB1 receptor-independent pathway and that 2-AG might function via a CB2-dependent pathway. The present findings show that the HEp-2 LSCC cell line releases the major endocannabinoids AEA and 2-AG, and that their supplementation inhibits tumor cell proliferation in vitro. Thus, cannabinoid ligands might represent novel drug candidates for laryngeal cancers, although functional in vivo studies are required in order to validate their potency.
  • Thumbnail Image
    Editorial
    Citation - WoS: 0
    Citation - Scopus: 0
    Editorial: Quality Assurance and Workflow Optimization for the Diagnosis and Treatment of Head and Neck Cancer
    (Frontiers Media Sa, 2024) Elicin, Olgun; Hosal, Sefik; Surgical Sciences
    [No Abstract Available]
  • Thumbnail Image
    Article
    Citation - WoS: 33
    Citation - Scopus: 35
    European Head and Neck Society Recommendations for Head and Neck Cancer Survivorship Care
    (Elsevier, 2022) Verdonck-de Leeuw, Irma; Hoşal, Ali Şefik; Dawson, Camilla; Licitra, Lisa; Eriksen, Jesper Grau; Hosal, Sefik; Singer, Susanne; Leemans, C. Rene; Hoşal, Ali Şefik; Surgical Sciences; Surgical Sciences
    Survivors of head and neck cancer can experience long-term consequences of the cancer and subsequent treatments even after the cancer has resolved. Increasingly clinicians are aware of the social, psychological, financial, and emotional impacts of these cancers, in addition to the support required for the physical symptoms. This review provides recommendations on the long-term management and support required for survivors of head and neck cancer in the European healthcare setting.